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Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease in
ageing individuals. It is now clear that genetic susceptibility and environmental factors play
a role in disease etiology and progression. Because environmental factors are involved
with the majority of the cases of PD, it is important to understand the role nutrition
plays in both neuroprotection and neurodegeneration. Recent epidemiological studies
have revealed the promise of some nutrients in reducing the risk of PD. In contrast, other
nutrients may be involved with the etiology of neurodegeneration or exacerbate disease
progression. This review summarizes the studies that have addressed these issues and
describes in detail the nutrients and their putative mechanisms of action in PD.
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INTRODUCTION
Parkinson’s Disease is a neurodegenerative disease that usually
develops late in life and is characterized by the loss of dopamin-
ergic neurons in the substantia nigra pars compacta (SNpc).
Most cases of Parkinson’s disease (PD) are idiopathic since their
cause is unknown. Genetic susceptibility and environmental fac-
tors (Warner and Schapira, 2003) that mediate mitochondrial
dysfunction, inflammation, abrogation of the autosomal-lysomal
autophagy system (Beal, 2003), and endoplasmic reticulum stress
(Ryu et al., 2002) play a role in disease development.
A growing body of evidence suggests that nutrition may play
an important role in PD. Epidemiological and biochemical stud-
ies have recently identified promising components in certain food
groups that may elicit neuroprotection in PD (Searles Nielsen
et al., 2013; Shaltiel-Karyo et al., 2013). However, inclusion or
exclusion of other food groups may trigger or exacerbate neu-
rodegeneration. In this review, we focus on the role nutrition
plays in promoting or slowing PD.
NUTRIENTS THAT MAY BE ASSOCIATED WITH AN
INCREASED RISK OR PROGRESSION OF PD
DAIRY PRODUCTS
Dairy product consumption and drinking milk may increase
one’s risk of PD independently of calcium intake (Hellenbrand
et al., 1996b; Chen et al., 2002; Park et al., 2005; Kyrozis et al.,
2013), particularly in men (Chen et al., 2007a). Nonetheless,
a positive association between milk consumption and PD risk
was also observed in women in one study (Saaksjarvi et al.,
2013). Preliminary research shows that individuals who con-
sume large amounts of dairy products may often have low
serum uric acid levels (Choi et al., 2005a). Serum urate and
uric acid is inversely correlated with the risk of PD and disease
duration (Weisskopf et al., 2007; Schlesinger and Schlesinger,
2008; Andreadou et al., 2009; Shen et al., 2013). The neuro-
protective effects of serum urate may be limited to men (Gao
et al., 2008; Shen et al., 2013) since the same is not observed
in women (O’Reilly et al., 2010). In addition, the possible pres-
ence of dopaminergic neurotoxins, including pesticides and poly-
chlorinated biphenyls in dairy products may increase the risk
of PD (Chen et al., 2002). Accordingly, postmortem studies
show higher levels of organochlorines, including dieldrin, an
organochlorine pesticide, and polychlorinated biphenyls in the
brains of PD patients compared to non-neurological controls
(Fleming et al., 1994; Corrigan et al., 1998). Yet, the presence
of dopaminergic neurotoxins may not be the only component
responsible for the relationship between dairy products and
PD. In fact, a strong positive association with the consump-
tion of milk, but not cheese or yoghurt has been reported
(Kyrozis et al., 2013). Therefore, other constituents in milk may
be detrimental with regards to PD and additional studies are
needed in order to identify them. The association between dairy
products and PD should be interpreted with caution, however,
as other studies have found conflicting results (Miyake et al.,
2011c).
NUTRIENTS THAT MAY BE ASSOCIATED WITH A
DECREASED RISK OR PROGRESSION OF PD
PHYTOCHEMICALS
The health benefits associated with the intake of phytochemi-
cals present in fruits and vegetables leads to decreased functional
decline associated with aging and may slow the progression of
PD (Liu, 2003). Epidemiological studies found that high intake
of fruits, vegetables and fish was inversely associated with PD
risk (Gao et al., 2007; Okubo et al., 2012). Dietary patterns,
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characteristic of a Mediterranean diet, are emerging as a potential
neuroprotective alternative for PD (Alcalay et al., 2012).
Most fruits and vegetables are rich sources of antioxidants,
including vitamins A, B (riboflavin), C, and E, which are
present in low levels in some PD patients. Numerous studies
have reported a decrease in peroxidase (Ambani et al., 1975),
glutathion-peroxidase activities (Kish et al., 1985), and glu-
tathione (Riederer et al., 1989) in the SN of PD patients post-
mortem; suggesting metabolic failure in antioxidant mechanisms
and chemical processes can lead to lipid peroxidation and parkin-
sonian characteristics (Uttara et al., 2009).
Although the antioxidant capacity of some fruits and veg-
etables is evidenced in numerous studies, a recent inves-
tigation raised caution about the antioxidant properties of
pomegranate. Contrary to the previously reported neuropro-
tective effects observed in Alzheimer’s Disease (Hartman et al.,
2006), pomegranate juice exacerbated oxidative stress and neu-
rodegeneration in a rotenone model of PD (Tapias et al., 2013).
However, the authors suggest that oxidative stress in a rotenone
model may be substantially overwhelming and promegranate
may act as a pro-oxidant.
Epidemiological studies have found a decrease in PD risk
in individuals who consume foods containing carotenoids and
β-carotene (Miyake et al., 2011a). Carotenoids possess antiox-
idant properties; they act as a reducing agent by protecting
lipids through oxidation interference and free radical entrapment
(Paiva and Russell, 1999). In mice, pretreatment with β-carotene
partially protected against MPTP-induced neurotoxicity (Perry
et al., 1985; Yong et al., 1986), but not in primates (Perry et al.,
1987). Lycopene, another carotenoid compound, reduces oxida-
tive stress and cognitive decline in a rotenone-induced rodent
model of PD (Kaur et al., 2011). One should be cautious however
about applying conclusions from animal models about the bene-
fits of carotenoids to humans, since most animals do not absorb
or metabolize carotenoids in a similar manner (Paiva and Russell,
1999).
Riboflavin is an integral component of the coenzymes flavin
adenine dinucleotide and flavin mononucleotide. Flavin coen-
zymes participate in oxidation–reduction reactions where they
are a major source of energy and are critical for carbohydrate,
fat and protein metabolism (Massey, 2000). It has been suggested
that riboflavin may be involved in glutathione depletion, cumu-
lative mitochondrial DNA mutations, disturbed mitochondrial
protein complexes, and abnormal iron metabolism (Coimbra
and Junqueira, 2003). Despite these characteristics, some stud-
ies found that riboflavin is not associated with the risk of PD
(Abbott et al., 2003; Murakami et al., 2010b), whereas another
study observed improved motor skills in PD patients with daily
supplementation of riboflavin for 6 months and elimination of
red meat (Coimbra and Junqueira, 2003). However, several lim-
itations of this study including omission of a placebo control
group and the investigators not being blinded have lead others to
question these findings (Ferraz et al., 2004). Another important
consideration is that lower protein consumption may affect the
absorption of levodopa (Pare et al., 1992; Crevoisier et al., 2003).
Therefore, the apparent benefit inmotor skills could have resulted
from a better absorption of levodopa as opposed to riboflavin
supplementation (Ferraz et al., 2004). In addition, intake of other
related B vitamins including folate, vitamin B6 and B12 are not
associated with a risk of PD (Chen et al., 2004). However, low
intake of vitamin B6 is associated with an increased risk of PD
(Murakami et al., 2010b). Larger placebo controlled blinded stud-
ies done over a longer period of time would be beneficial for
determining if riboflavin or other related B vitamins are useful
supplements for PD patients.
Recently, dietary intake of nicotine-containing vegetables from
edible Solanaceae including tomatoes, potatoes, and peppers,
was associated with a reduced risk of PD in men and woman
who had never smoked cigarettes or tobacco (Searles Nielsen
et al., 2013). It remains unclear as to whether the observed
protective effect was due to the nicotine content or other com-
ponents of this group of vegetables. Cruciferous vegetables such
as cauliflower, cabbage, and broccoli, are another group of veg-
etables rich in antioxidants with neuroprotective capacity. For
example, sulforaphane and erucin, are potent naturally occurring
isothiocyanates found in cruciferous vegetables with antioxi-
dant properties. Treatment with sulforaphane ameloriated motor
deficits and protected dopaminergic neurons in a 6-OHDA
mouse model of PD (Morroni et al., 2013). Similarly, erucin
provided neuroprotective effects by preventing oxidative damage
induced by 6-OHDA in an in vitro model (Tarozzi et al., 2012).
Both, sulforaphane and erucin appear to be promising neuro-
protective agents in chronic neurodegenerative diseases (Tarozzi
et al., 2013). Taken together, these findings highlight the effects
of some vegetables, fruits and constituents they contain as having
neuroprotective potential.
Omega-3 (DHA)
Omega-3 polyunsaturated fatty acids (PUFAs) appear to be neu-
roprotective for several neurodegenerative diseases (Bousquet
et al., 2011a). There have been no studies in PD patients that
address whether omega-3s are neuroprotective, however, one
study showed that supplementation with omega-3 PUFA reduced
depression in PD patients (Da Silva et al., 2008). Current research
focuses specifically on the omega-3 fatty acid docosahexaenoic
acid (DHA). DHA is an essential factor in brain growth and devel-
opment (Horrocks and Yeo, 1999) and has anti-inflammatory
potential due to its ability to inhibit cyclooxygenase-2 (Massaro
et al., 2006). DHA protects neurons against cytotoxicity, inhi-
bition of nitrogen oxide (NO) production, and calcium (Ca2+)
influx. DHA also increases the activities of antioxidant enzymes
glutathione peroxidase and glutathione reductase (Wang et al.,
2003). Furthermore, DHA supplementation reduced apopto-
sis in dopaminergic cells (Ozsoy et al., 2011) and replaced
omega-6-PUFAs in the brains of mice post-MPTP treatment
(Bousquet et al., 2008). Short-term administration of DHA
reduced levodopa-induced dyskinesias in parkinsonian primates
by up to 40% (Samadi et al., 2006). Long-term administration of
uridine and DHA increased the amount of neural phosphatides in
synaptic membranes (Wurtman et al., 2006) and dendritic spines
in rodents (Sakamoto et al., 2007). In addition, a reduction in
parkinsonian behaviors and elevated dopamine (DA) levels in
6-OHDA rodents was observed after treatment with these supple-
ments (Cansev et al., 2008). Further research on DHA intake in
Frontiers in Aging Neuroscience www.frontiersin.org March 2014 | Volume 6 | Article 36 | 2
Seidl et al. Nutrition in Parkinson’s disease
PD patients is needed to assess whether it is beneficial in slowing
disease progression.
The protective effects of DHA are mediated by a metabolic
derivative known as neuroprotectin D1 (NPD1) (Bazan, 2009;
Serhan and Petasis, 2011). NPD1 protects neurons against oxida-
tive stress, inflammation, the disruption of the cytoskeleton,
and from the activation of apoptotic signaling pathways. DHA
may protect the brain by increasing glutathione reductase activ-
ity that results in decreased accumulation of oxidized proteins
(Calon et al., 2004; Wu et al., 2004), lipid peroxide and reac-
tive oxygen species (ROS) (Hashimoto et al., 2005). DHA also
inactivates caspase activation signaling pathways (Calon et al.,
2005), inhibits hyperphosphorylation of tau (Green et al., 2007)
and regulates the PI3K/Akt cascade (Akbar and Kim, 2002).
Other potential mechanisms of action of DHA include regula-
tion of inflammation, transcription, and cell membrane prop-
erties (De Urquiza et al., 2000; Salem et al., 2000; Jump,
2002).
The precursor to DHA, eicosapentaenoic acid (EPA) is neu-
roprotective in experimental models of PD (Song et al., 2009;
Meng et al., 2010; Taepavarapruk and Song, 2010; Luchtman
et al., 2012). In in vitro models of PD, EPA attenuated an
MPP+-induced reduction in cell viability and suppressed pro-
inflammatory cytokines (Luchtman et al., 2013). A diet rich in
EPA diminished hypokinesia induced by MPTP in mice and
ameliorated procedural memory deficit (Luchtman et al., 2013).
Because DHA and EPA provide neuroprotection in animal
models, more research is warranted to determine if they are ben-
eficial for PD patients. This could be accomplished by following
a large group of individuals at risk for PD, some of who are ran-
domly chosen to receive a supplement and other who receive a
placebo. The participants could be followed over several years
to determine if they develop PD. Alternatively, a large interven-
tion study testing supplements in patients at various stages of
PD might reveal whether motor and/or cognitive symptoms are
reduced.
Soy (GENISTEIN)
The primary soybean isoflavone genistein is a source of protein
that appears to be neuroprotective in ovariectomized rats follow-
ing 6-OHDA injection, thus suggesting it may be useful for the
prevention of PD in post-menopausal women (Kyuhou, 2008). In
PD, genistein treatment resulted in dopaminergic neuron protec-
tion from lipopolysaccharide (LPS)-induced injury via inhibition
of microglia activation (Wang et al., 2005). Genistein pretreat-
ment improved spatial learning andmemory in parkinsonian rats
(Sarkaki et al., 2009) and restored tyrosine hydroxylase (TH),
dopamine transporter (DAT) and Bcl-2 mRNA expression in the
midbrain of MPTP-treated animals (Liu et al., 2008). Restored
levels of DA and its metabolites, dihydroxyphenylacetic acid,
and homovanillic acid, in the striatum were also observed after
genistein administration. Additionally, genistein attenuated rota-
tional behavior, protected SNpc neurons (Baluchnejadmojarad
et al., 2009), and preserved motor function (Kyuhou, 2008) from
6-OHDA toxicities. Genistein’s neuroprotective actions may reg-
ulate mitochondria-dependent apoptosis pathways and suppress
ROS-induced NF-κB activation (Qian et al., 2012). These studies
suggest that it may be worthwhile to test the neuroprotective
benefits of genistein in a clinical trial.
CAFFEINE
Caffeine is one of the most widely consumed substances. The
health promoting benefits of caffeinated beverages is supported
by numerous epidemiological studies (Prakash and Tan, 2011;
Tanaka et al., 2011). An inverse association between PD and
coffee, and caffeine from non-coffee sources, has been reported
(Hellenbrand et al., 1997; Fall et al., 1999; Ascherio et al.,
2001). In general, animal studies also indicate that caffeine is
neuroprotective. The administration of caffeine to maneb- and
paraquat-treated rodents reduced the number of degenerating
dopaminergic neurons, microglial cells and nitrite content, while
normalizing expression of IL-1β, p38 MAPK, NF-kB, and TK
(Kachroo et al., 2010; Yadav et al., 2012). Acute and chronic
administration of caffeine also reduced the effect of MPTP (Chen
et al., 2001) and 6-OHDA treatment on striatal DA loss (Joghataie
et al., 2004) and motor dysfunctions (Joghataie et al., 2004;
Aguiar et al., 2006) in rats. Caffeine treatment partially restores
DA metabolites in rats following 6-OHDA lesions (Aguiar et al.,
2006), and provides neuroprotection in MPTP models of PD (Xu
et al., 2010), thus extending its beneficial effects. It is important
to note that a caffeine tolerance does not develop with long-term
exposure in mice (Xu et al., 2002) and neuroprotection is still
apparent with caffeine intake after the onset of neurodegeneration
in rats (Sonsalla et al., 2012).
Genetic and pharmacological data from rodent studies indi-
cate that caffeine reduces dopaminergic toxicity and slows dis-
ease progression through antagonism of adenosine A2A receptors
(Morelli et al., 2010; Prediger, 2010; Xiao et al., 2011; Sonsalla
et al., 2012). Inhibition of glutamate neurotransmission using
A2A receptor antagonists, may relieve motor symptoms and pro-
vide neuroprotection in models of late-stage PD (reviewed in
Popoli et al., 2004; Chen et al., 2007b). However, methylxan-
thine derivatives containing properties of monoamine oxidase B
(MAO-B) inhibition, like 8-(3-chlorostyryl) caffeine, may cause
oxidative stress via dysfunctional vesicular monoamine trans-
porter 2 (VMAT2) and DA storage mechanisms early in PD
(Golembiowska and Dziubina, 2012). Currently, clinical studies
are underway to evaluate several A2A receptor antagonists for
symptomatic relief and slowing of disease progression (reviewed
in Hickey and Stacy, 2011). Caffeine has also shown cytoprotec-
tive effects through activation of the PI3K/Akt signaling pathway
in SH-SY5Y cells (Nakaso et al., 2008). Therefore, caffeine’s abil-
ity to down-regulate NO production, neuroinflammation, and
microglial activation through these pathways may contribute to
neuroprotection (Yadav et al., 2012). It is not fully established,
however, that caffeine’s neuroprotective role is the sole reason for
reduced risk of PD. Nor is it known whether the association is
causal rather than reverse causation; the protective effect of caf-
feine could also reflect an effect of symptoms of PD on caffeine
consumption.
Estrogen has significant effects on caffeine’s neuropro-
tective capabilities. Epidemiological studies have consistently
demonstrated a greater improvement in male than female
Parkinson’s patients (Ascherio et al., 2001; Costa et al., 2010).
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Interestingly, post-menopausal women who are not taking
hormone-replacement therapy receive the same neuroprotective
benefits as men (Ascherio et al., 2001). However, high caffeine
consumption was associated with an increased risk of PD among
women using hormones (Ascherio et al., 2003). More recently,
findings from a larger prospective study are consistent with a
neuroprotective effect of caffeine intake in men and an atten-
uated effect in women due to hormone replacement therapy
(Palacios et al., 2012a). With regards to animal models, estro-
gen and caffeine co-administration in MPTP-treated mice, pre-
vented neuroprotection in males and females (Xu et al., 2006).
Together these studies suggest that the beneficial effects of caf-
feine may be limited to men and post-menopausal women not
receiving hormone-replacement therapy. However, an open-label
study examining caffeine’s symptomatic effects and tolerability in
patients demonstrated improved non-motor aspects of PD with
no gender differences (Altman et al., 2011). Currently adenosine
A2A antagonists and caffeine are in phase II and III clinical tri-
als for the symptomatic treatment of PD (Barkhoudarian and
Schwarzschild, 2011).
TEA
Several epidemiological studies have addressed the influence of
drinking tea (Camellia sinensis) on the risk of PD. A case-control
study of Chinese PD patients showed that regular tea drinking
protects against PD (Chan et al., 1998). Another study compli-
mented the Chinese PD study showing a reduced risk for PD
with tea consumption (two cups/day) (Checkoway et al., 2002).
Similarly, a large prospective study showed a reduced risk of inci-
dent PD in subjects who habitually drank three or more cups
of tea per day (Hu et al., 2007). A retrospective study associated
drinking of more than three cups of tea per day with a delayed
onset of motor symptoms in Israeli PD patients (Kandinov et al.,
2009). Unfortunately, no distinction between green and black tea
was made in these studies.
Several reports have revealed that both black and green tea
exert neuroprotective effects in PD animal models (Bastianetto
et al., 2006; Chaturvedi et al., 2006). Polyphenols in green and
black tea extracts provide highly potent antioxidant-radical scav-
enging activities in brain mitochondrial membrane fractions
(Zhao, 2009). In addition, polyphenols in tea reduce occurrence
of disease and provide neuroprotection in cell culture and ani-
mal models (Nie et al., 2002; Pan et al., 2003b; Guo et al.,
2007). In black tea, the polyphenol theaflavin (TF) possess a
wide variety of pharmacological properties including antioxida-
tive, antiapoptotic, and anti-inflammatory effects (Aneja et al.,
2004; Gosslau et al., 2011). TF-mediated neuroprotection against
MPTP-induced dopaminergic neurodegeneneration in rodents
was evidenced by increased expression of nigral TH, DAT and
reduced expression of apoptotic markers (Anandhan et al., 2012).
Similarly, the polyphenol (–)-epigallocatechin-3-gallate
(EGCG) in green tea shows promise in neuroprotection, but
one study showed that green tea drinking was unrelated to the
risk of PD (Tan et al., 2008). EGCG inhibits nitric oxide and
tumor necrosis factor-α secretion from LPS-activated microglia
in dopaminergic mesencephalic cells (Li et al., 2004). Given
that microglia play a key role in the generation of free radicals
and inflammatory factors in the brain, EGCG was classified as
neuroprotective in vivo (Li et al., 2004). Additionally, EGCG
improved cell viability and attenuated MPP-induced intracellular
ROS formation via the SIRT1/PGC-1α signaling pathway in MPP
induced PC12 cells (Ye et al., 2012). EGCG reduced neuronal cell
death and induced nitric oxide synthase (NOS) expression in an
MPTP mouse model of PD, thus providing further evidence for
its neuroprotection via NO reduction (Kim et al., 2010). Oral
pretreatment with EGCG prevented dopaminergic neuron loss
in MPTP-treated mice (Levites et al., 2001). In contrast, another
study found subtle symptomatic relief but no neuroprotection
with similar dose of EGCG in rats following a 6-OHDA lesion
(Leaver et al., 2009). The differences between the results from
these two studies may reflect the different mechanisms by which
MPTP and 6-OHDA exert their neurotoxic effects. Also, the poor
bioavailability of oral EGCG in rats may explain why similar
doses led to different results in animal models (Kim et al., 2000).
Computational molecular modeling has shown that EGCG is
a potent, non-competitive inhibitor that invokes various cellu-
lar neuroprotection/neurorescue mechanisms (Zhu et al., 2008).
EGCG’s mechanisms of action include iron-chelation, scaveng-
ing of oxygen and nitrogen radical species, activation of protein
kinase C (PKC) signaling pathway and expression of pro-survival
genes (Weinreb et al., 2009), and restoration of reduced PKC and
extracellular signal-regulated kinases (ERK1/2) activities caused
by 6-OHDA toxicity (Zhao, 2009). Tea and/or EGCG prevent
neurotoxin-induced cell injury (Weinreb et al., 2004), MPTP-
induced dopaminergic neurodegeneration and restore striatal
levels of DA and its metabolites (Levites et al., 2001; Choi et al.,
2002). Green tea polyphenols could also protect dopaminer-
gic neurons against MPTP-induced injury by exerting inhibitory
effects on DA-transporters, which block the uptake themetabolite
MPP+ (Pan et al., 2003a).
In summary, tea consumption seems to be a promising lifestyle
choice that may slow age-related deficits and neurodegenerative
diseases. Given the evidence from preclinical studies, green tea
polyphenols are currently being tested as a treatment for de novo
PD patients (ClinicalTrials.gov identifier: NCT00461942).
ALCOHOL
Alcohol may exert neuroprotective effects in PD. One case-
controlled study found an inverse association between total alco-
hol consumption and PD (Ragonese et al., 2003). A recent study
suggests that low to moderate beer consumption may be associ-
ated with a lower PD risk, whereas greater liquor consumption
may increase the risk of PD (Liu et al., 2013). Contrary to these
findings, most of the epidemiological studies do not support
an association between alcohol consumption and risk of PD
(Benedetti et al., 2000; Checkoway et al., 2002; Hernan et al., 2003;
Palacios et al., 2012b). Currently, the association between alcohol
consumption and the risk of PD remains poorly understood.
Despite the conflicting results from epidemiological studies,
specific components found in red wine including resveratrol and
quercetin, may elicit neuroprotection against PD. Administration
of resveratrol or quercetin before MPTP treatment reduced apop-
totic cell death and modulated expression of Bax and Bcl-2
in PC12 cultures (Bournival et al., 2009, 2012). Resveratrol
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has elicited neuroprotective effects by preventing behavioral,
biochemical, and histopathological changes that occur in PD
animal models (Bureau et al., 2008; Khan et al., 2010). A diet con-
taining resveratrol protects dopaminergic neurons and attenuates
motor coordination in MPTP rodent models (Blanchet et al.,
2008; Lu et al., 2008). Many studies suggest that the antioxi-
dant actions of resveratrol are responsible for the neuroprotection
from MPP+ toxicity (Alvira et al., 2007; Okawara et al., 2007).
Mechanistically, resveratrol reduces inflammation by trapping
free radicals and preventing apoptosis of DA-producing neu-
rons (Blanchet et al., 2008; Jin et al., 2008; Lu et al., 2008).
In vitro studies showed that resveratrol protects DA neurons
against LPS-induced neurotoxicity through the inhibition of
microglial activation and subsequent pro-inflammatory factors
(Zhang et al., 2010). Resveratrol-mediated neuroprotection has
also been attributed to the inhibition of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase and possibly activa-
tion of SIRT1 (Pallas et al., 2009; Zhang et al., 2010). However, one
study suggested that SIRT1 activation does not play a major role
in the protective effect of resveratrol against MPP+ cytotoxicity
(Alvira et al., 2007). Although the evidence from in vitro and ani-
mal studies is promising, epidemiological studies do not support
an association between red wine consumption and PD (Palacios
et al., 2012b). Further research on the type and amount of dietary
alcohol intake and the risk of PD would be very beneficial.
NUTRIENTS WITH A QUESTIONABLE ROLE IN PD
FAT
Dietary fat has shown inconsistent results in relation to PD.
Rodent studies show diets high in fat exacerbate the progression
of parkinsonism by exhibiting increased DA depletion in the SN,
striatum, and nigrostriatal pathway (Choi et al., 2005b; Morris
et al., 2010; Bousquet et al., 2011b). With regards to humans,
epidemiological studies found a higher risk of PD among indi-
viduals with greater intake of total animal fat (Logroscino et al.,
1996; Anderson et al., 1999; Johnson et al., 1999; Chen et al.,
2003), whereas other studies show no significant relationship
between PD and animal fat (Hellenbrand et al., 1996a; Chen et al.,
2002, 2003; Powers et al., 2003). Moreover, the positive associa-
tion between fat and PD risk reported earlier (Anderson et al.,
1999) was not replicated in a larger study (Powers et al., 2003).
Nonetheless, the conflicting results from these studies may be
attributed to the specific type of fat in the diet, saturated or unsat-
urated, which is not always specified. Nor is the amount of animal
protein consumed to supply the fat intake discussed.
In animal studies and clinical trials, a ketogenic diet, which
is high in fat, provided symptomatic and beneficial disease-
modifying activity in PD (Gasior et al., 2006). In fact in a small
clinical trial, five PD patients on a hyperketonemia diet that sub-
stituted unsaturated for saturated fats showed improvement on
the Unified Parkinson’s Disease Rating Scale (Vanitallie et al.,
2005). It should also be noted that the patients on the ketogenic
diet ate only 8% protein. Low protein diets lead to better levodopa
bioavailability (Pincus and Barry, 1987). It is therefore possi-
ble that the observed improvement may have been due to better
absorption of synthetic dopamine in four of the patients since
one patient was not taking anti-parkinson medication (Vanitallie
et al., 2005). Because of the limited number of patients, the diffi-
culty in adhering to a hyperketonemia diet, and the lack of healthy
controls, the authors were not able to rule out a placebo effect.
The promising results from this preliminary study suggest that
another clinical trial of the ketogenic diet that includes a larger
number of patients is warranted.
Dietary intake of PUFAs and monounsaturated fatty acids
(MUFAs) might influence the risk of PD (Abbott et al., 2003; De
Lau et al., 2005). It has been reported in other disease models that
PUFA’s have anti-inflammatory and neuroprotective properties
(Blok et al., 1996; Simopoulos, 1999; Youdim et al., 2000; Kim
et al., 2001) and MUFAs are thought to reduce oxidative stress
(Colette et al., 2003; Moreno and Mitjavila, 2003). Unsaturated
fatty acids are important constituents of neuronal cell membranes
and the fatty acid composition of cell membranes is affected
by diet. It has been demonstrated in other disease models that
infants and young animals with dietary deficiencies in MUFAs
and PUFAs have a decrease in brain function (Fernstrom, 1999;
Simopoulos, 1999; Youdim et al., 2000; Moreno and Mitjavila,
2003). Moreover, it has been shown that PUFA intake is consis-
tently associated with lower PD risk, and dietary fats modified
the association of PD risk with pesticide exposure (Kamel, 2013;
Kamel et al., 2013). Notably, PD was inversely associated with
the N-3 precursor α-linolenic acid, an essential fatty acid, in a
meta-analysis comprising nine studies (Kamel et al., 2013). The
health benefit effects of α-linolenic acid may be due to its poten-
tial role in protecting against oxidative stress and inflammation
(Hassan et al., 2010; Robinson and Mazurak, 2013; Zhang et al.,
2013). These studies suggest that a diet high in PUFAs and low
in saturated fats might reduce the risk of PD and protect from
the toxic effects of neurotoxins, such as those possibly present
in milk.
Alternatively, saturated fat could modify the risk of PD by
affecting PUFA metabolism and inducing adverse changes in cell
membrane lipid composition (Peers, 1997). Thus, fatty acids may
contribute to an increased risk of PD via oxidative stress. PUFAs
are concentrated in neuronal membranes and play a role in
oxidative radical formation. Lipid peroxidation results in oxida-
tive damage and can modify lipid composition of membranes,
potentially leading to neuronal death (Farooqui and Horrocks,
1998). In addition, adverse essential fatty acid composition in
the mitochondrial membrane may also induce phosphorylation
uncoupling, causing energy failure (Peers, 1997). Thus, a high
concentration of PUFAs may contribute to neural oxidative stress
through lipid peroxidation. Additionally, PD patients have higher
concentrations of PUFA peroxidation metabolites and lower con-
centrations of PUFA and glutathione in the SN compared to
healthy controls, further supporting the hypothesis that energy
failure may facilitate the onset and/or progression of PD (Chen
et al., 2003). However, higher concentrations of PUFA perox-
idation metabolites and lower PUFA may arise from several
environmental factors in addition to nutrients.
The importance of fats in the pathogenesis of PD in some
patients is suggested by genetic studies. Mutations in PARK2,
which encodes the PD related factor Parkin, lead to an early
onset familial form of PD (Kitada et al., 1998). Parkin is part
of the E3 ubiquitin ligase complex that targets specific substrates
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for degradation via the ubiquitin−proteasome pathway (Shimura
et al., 2000). Recently, it was shown that Parkin is a lipid-
dependent regulator of fat uptake in mice and patient cells carry-
ing mutations in PARK2 (Kim et al., 2011). These studies suggest
that genetic mutations in the uptake or breakdown of fat may be
associated with PD.
Lipid and cholesterol metabolism may also play a role in
the pathogenesis of idiopathic PD, however the association
between cholesterol and PD is highly debated (Hu, 2010).
Lower plasma cholesterol concentrations (Lamperti, 1991) and
decreased cholesterol biosynthesis is observed in cell lines from
PD patients (Musanti et al., 1993), suggesting that low levels of
cholesterol may play a role in PD development and/or progres-
sion. In contrast, higher total serum cholesterol may be associated
with a modest slower progression of PD (Huang et al., 2011) and
lower iron content in SN and globus pallidus in PD patients (Du
et al., 2012). Interestingly, the association with increased choles-
terol levels and decreased PD was seen primarily in women (De
Lau et al., 2006). One possible explanation about the lack of an
association between cholesterol levels and PD in men may be
due to the gender differences of plasma concentration levels of
the antioxidant coenzyme Q10 (De Lau et al., 2006), which are
significantly higher in men than in women (Kaikkonen et al.,
1999). In this regard, it should be noted that coenzyme Q10
has shown neuroprotective properties in numerous PD studies
(Shults et al., 2004; Cleren et al., 2008). More recently, the total;
HDL cholesterol ratio was found to be inversely associated with
disease duration, thereby suggesting an effect of cardiometabolic
protection in PD (Cassani et al., 2013). The results from this study
must be interpreted with caution since no healthy controls were
included in the analysis.
The studies cited above reflect our incomplete understanding
regarding the association between fat intake and PD. The role
that fat plays in PD is most likely related to the type of fat in
the patient’s diet (De Lau et al., 2005), the patient’s HDL/LDL
ratio, total cholesterol levels and genetic factors. Ideally, large
prospective randomized controlled studies are needed to clarify
the associations between fat intake and PD.
MEAT
Meat is another source of animal fat and its consumption may
be associated with the incidence of PD (Anderson et al., 1999)
but the evidence from prospective studies is limited (Gaenslen
et al., 2008). Interestingly, intake of processed meat and sausages
was inversely associated with PD risk in women (Saaksjarvi et al.,
2013). This finding is surprising given the higher incidence of
mortality, cardiovascular diseases, and diabetes associated with
processed meat consumption (Micha et al., 2010; Rohrmann
et al., 2013). In the case of redmeat, a positive association between
red meat consumption and PD may be explained by the heme
content that may act as a toxin when not digested properly. Heme
is found in other meats also but not to the same extent. Hemin
increases intracellular iron concentrations and hydroxyl radi-
cal production, contributing to iron deposits and mitochondrial
damage (Schipper, 2000). In this context, iron intake from dietary
nutrients may be related to risk for PD (Powers et al., 2003) but
the evidence for this association is conflictive (Logroscino et al.,
1998, 2008). Despite the inconsistent results, higher intake of iron
is associated with neuroprotection in PD (Miyake et al., 2011b).
Notwithstanding the positive results, the authors of this study
noted that evaluation of dietary intake for 1 month prior to com-
pleting the questionnaire by the participants might not properly
represent their typical diets.
CARBOHYDRATES
It has been suggested that carbohydrates increase DA production
in the brain by allowing easier passage of the DA precursor,
tyrosine, through the blood-brain barrier into cerebrospinal fluid
(Fernstromet al., 1979;Wurtman et al., 2003). Carbohydrateswith
high glycemic index decrease the risk of PD by an insulin-induced
increase in brain DA (Murakami et al., 2010a). A balanced diet of
carbohydrate and protein mixture improved motor performance
in PD patients (Berry et al., 1991). Yet, epidemiological studies
aboutcarbohydrateconsumptionandPDremain inconclusive.For
example, theNursesHealthStudyandHealthProfessionalsFollow-
up Study reported a non-significant direct association in women
and inverse association in men for carbohydrate consumption
and PD risk (Chen et al., 2003). In contrast, other studies have
shown a positive association for total carbohydrate consumption
and PD (Hellenbrand et al., 1996a; Abbott et al., 2003).
High carbohydrate diets are associated with an increased risk
of type 2 diabetes (T2DM) (Salmeron et al., 1997a,b; Oba et al.,
2013). Interestingly, numerous epidemiological studies indicate
T2DM is associated with an increased risk of PD (Schernhammer
et al., 2011; Xu et al., 2011; Sun et al., 2012; Cereda et al., 2013) but
the evidence presented is conflictive (Simon et al., 2007; Palacios
et al., 2011; Noyce et al., 2012). Nonetheless, T2DM is associ-
ated with more severe motor symptoms in PD (Kotagal et al.,
2013). One possible explanation for the link between both chronic
diseases is that alterations in common biological pathways may
lead to neurodegeneration in patients with T2DM (Santiago and
Potashkin, 2013b). In this regard, emerging research is begin-
ning to elucidate the molecular networks and potential mecha-
nisms implicated in both diseases (Santiago and Potashkin, 2013a;
Mattson, 2014; Wang et al., 2014). Since carbohydrates are an
important part of people’s diets and its high consumption may
increase risk for T2DM (Salmeron et al., 1997a,b; Oba et al.,
2013) further research on the amount and type of dietary car-
bohydrates consumed in relationship to the risk of PD would be
very beneficial.
VITAMIN D, C, AND E
Vitamin D deficiency is prevalent in PD patients (Sato et al.,
1997); yet, it is unclear if a reduction in Vitamin D is a cause
or consequence of PD. Vitamin D plays a role in regulating
Ca2+ homeostasis (Garcion et al., 2002; Chan et al., 2009)
and if disrupted, SNpc dopaminergic neuron loss is accelerated
(Gleichmann and Mattson, 2011). This suggests that dietary reg-
ulation of vitamin D may be effective in protecting individuals
from PD or slowing PD progression. In animal and cell culture
models of PD, vitamin D supplementation was found to be ben-
eficial in slowing disease progression (Wang et al., 2001; Smith
et al., 2006; Holick, 2007). In human studies, however, high con-
sumption of food containing vitamin D increased the risk of PD
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(Anderson et al., 1999). More recently, vitamin D3 supplemen-
tation stabilized PD patients’ motor symptoms, preventing an
increase in the Hoehn and Yahr stage, compared to a placebo-
controlled group (Suzuki et al., 2013). It remains unknown if a
reduction in vitamin D stemming from nutritional deficiencies
causes an increase in PD and/or if an environmental factor such
as UV radiation or exposure to sunlight plays a role. Therefore,
more research needs to be done in order to link vitamin D sup-
plementation and its effective in protecting individuals from PD
or PD progression.
Vitamin C or ascorbate is highly concentrated in the cen-
tral nervous system and its neuroprotective capabilities show
promise in reducing lipid peroxidation levels and increasing cata-
lase activity (Santos et al., 2008). Higher intake of vitamin C
correlates with an increase risk of PD (Scheider et al., 1997).
In contrast, in a case-controlled study, individuals consuming
a diet rich in vitamin C showed a 40% reduction of PD risk
(Hellenbrand et al., 1996a). Interestingly, in a pilot study in which
high doses of vitamin C and E were given to early stage PD
patients, a decrease in disease progression was observed (Fahn,
1992). Despite this progress, other studies have not found a signif-
icant association between intake of dietary vitamin C or vitamin
C supplements and risk of PD (Zhang et al., 2002; Etminan et al.,
2005). Collectively, the association of vitamin C and PD risk
remains inconclusive and more studies are needed to clarify this
association.
Vitamin E supplementation provides protective effects on DA
neurons in the SNpc (Roghani and Behzadi, 2001), reduce DA
loss (Lan and Jiang, 1997), and protect against paraquat toxi-
city (Storch et al., 2000; Osakada et al., 2004) in rodents and
in vitro. Pretreatment with vitamin E reduces lipid peroxida-
tion levels (Lan and Jiang, 1997), but depletion of striatal DA
was not attenuated in animals (Gong et al., 1991; Chi et al.,
1992). The potential benefits seen in vitamin E may be linked to
its chain-breaking capabilities in biological membranes, prevent-
ing induced oxidative damage by trapping reactive oxyradicals.
Yet, other studies have shown that vitamin E has no protective
effects against DA-induced toxicity in PC12 cells (Offen et al.,
1996) and only partial protection in MPTP-treated marmosets
(Perry et al., 1987). A meta-analysis showed a protective effect
against PD in humans with both moderate and high intake
of vitamin E (Etminan et al., 2005), with a more significant
effect observed in men than women (Zhang et al., 2002). In
contrast, clinical trials show no neuroprotective benefits from
vitamin E in PD patients (Fernandez-Calle et al., 1992; Lewitt,
1994).
Although researchers have started investigating the effect of
individual nutrients through supplements the results of these
studies remain inconclusive. Antioxidants are much more effec-
tive in combinations and therefore a combination of vitamins
may be beneficial, perhaps acting synergistically. Thus, we sug-
gest that choosing a diet that contains a variety of foods that
are rich in multiple phytochemicals and other bioconstituents
may provide a means of disease management. The total elimi-
nation of any one food group is not recommended. Additional
prospective nutritional studies should help to resolve this
issue.
NUTRITION, THE GENOME, AND THE EPIGENOME
A poor diet will have a negative impact on an individual’s health.
With regards to neurodegeneration, nutrition affects multiple
aspects of neurodevelopment, neurogenesis and the functions
of neurons and neural networks (Dauncey and Bicknell, 1999).
Nutrition-gene interactions play a critical role in dysfunction
and disease (Dauncey, 2012). Individual differences in genes such
as single nucleotide polymorphisms, mutations and copy num-
ber variants significantly modify the effects of nutrition on gene
expression (Dauncey, 2013).
A person’s epigenome is just as important as their genome.
An individual’s epigenome reflects the interaction of the per-
son’s genome with their environment. Epigenomic modifications
include DNAmethylation, which may alter protein-DNA interac-
tion and result in genes being expressed or turned off. Another
type of modification is histone modification, which may lead to
changes in DNA packaging. Histone modification may also lead
to switching a gene on or off by making the DNA packaging
more or less accessible to proteins. In addition, epigenetic reg-
ulation of gene expression through small non-coding RNAs is
environmentally regulated. Epigenetic regulation of gene expres-
sion plays an important role in development and pathological
processes (Dauncey et al., 2001; Babenko et al., 2012; Dauncey,
2012; Hackett et al., 2012; Park et al., 2012; Qureshi and Mehler,
2013). What a person eats and drinks will impact their epigenome
(Dauncey, 1997, 2012; Langie et al., 2012). Currently the details
about how individual nutrients affect the epigenome generally
remain unknown. This area of nutrition research is still in its
infancy. If we want to improve peoples’ health it will be important
to emphasize this area of research in the future because epige-
netic changes also impact future generations since they may be
inherited.
CONCLUSIONS
Currently, there is an abundance of preliminary evidence that
indicates that some nutrients may increase an individual’s
risk for PD, while others may be neuroprotective (Figure 1,
Supplementary Tables 1, 2). These results are not unexpected
FIGURE 1 | Role of nutrients in PD. Epidemiological and biochemical
studies suggest that inclusion or exclusion of certain food groups may elicit
neuroprotection or neurodegeneration. Foods are shown on a spectrum.
Foods shown in the red promote neurodegeneration and foods in green
promote neuroprotection. Foods shown in the middle (or yellow) part of the
spectrum have conflicting results and need to be studied further to assess
if they play a role in neurodegeneration or neuroprotection.
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since nutrients affect mitochondrial energy function and pro-
vide vital antioxidant functions that ameliorate the free-radical
byproducts of oxidative phosphorylation. A poor diet may lead
to increased oxidative stress, which could impede the antioxi-
dant defense system. In contrast, a well-balanced diet rich in
a variety of foods, including numerous servings of vegetables
and fruits (especially those containing nicotine) and moderate
amounts of omega-3 fatty acids, tea, caffeine, and wine may
provide neuroprotection.
In spite of promising effectiveness of these nutrients in PD,
we lack definitive evidence-based answers as a result of lim-
ited large prospective randomized controlled studies designed
to address these issues. Indeed, there are several limitations in
some epidemiological studies assessing dietary factors and PD
that merit further attention. For example, the assumption that
dietary patterns remain unchanged over time is a major limi-
tation. Information on diet during development would be very
helpful and may weaken or strength a result. In addition, patients
with PD may experience non-motor symptoms at early stages
such as constipation, dysphagia, depression, and hyposmia that
may affect dietary choices and therefore may be responsible for
the impairment of nutritional status observed in PD (Ponsen
et al., 2004; Barichella et al., 2009). These factors may remain
undetected and therefore not properly reported. Incorporation
of these critical factors into clinical practice and epidemiological
studies will greatly improve the reliability of studies assessing the
role of nutrients in PD.
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